Oxford Nanopore Technologies (LSE:ONT) has reported a strong trading performance for 2025, with full-year revenue expected to reach approximately £223–224 million. This represents growth of around 22% on a reported basis and 24% at constant currency, modestly ahead of the company’s prior guidance.
Revenue growth was broad-based across both regions and end markets. All major geographic areas delivered constant-currency growth of more than 20%. By end market, Clinical revenue led performance with growth of around 60%, followed by BioPharma at roughly 30% and Applied Industrial at about 27%. Research revenue increased by approximately 15%, despite ongoing funding pressures in that segment. Product demand was particularly strong for the PromethION platform range, which recorded year-on-year growth of more than 40%, highlighting continued uptake of the company’s high-throughput sequencing systems.
Oxford Nanopore also noted continued progress toward profitability and closed 2025 with around £302 million in cash and liquid investments, exceeding market expectations and providing a robust financial base to support its long-term strategy. The company is scheduled to release its preliminary results for the year ended 31 December 2025 on 2 March 2026, alongside a management presentation and question-and-answer session.
From an investment perspective, the outlook reflects a balance between encouraging operational momentum and ongoing financial and technical challenges. While revenue growth and a strategic emphasis on improving profitability are positive signals, broader market conditions and current financial metrics continue to present meaningful risks.
More about Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies PLC is a life sciences and biotechnology company that has developed nanopore-based sensing technology enabling real-time, high-performance analysis of DNA and RNA. Its sequencing platforms are deployed in more than 125 countries across research, clinical, biopharma, applied industrial and pathogen surveillance applications, with potential uses spanning healthcare, food and agriculture.
Leave a Reply